Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors.

Paprottka, Karolin J; Galiè, Franziska; Ingrisch, Michael; Geith, Tobias; Ilhan, Harun; Todica, Andrei; Michl, Marlies; Nadjiri, Jonathan; Paprottka, Philipp M

doi:10.3390/cancers13215399

2021

Zurück
Zurück zum Anfang der Trefferliste
Dauerhafter Link zum angezeigten Objekt

Titel:: Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors.
Dokumenttyp:: Journal Article
Autor(en):: Paprottka, Karolin J; Galiè, Franziska; Ingrisch, Michael; Geith, Tobias; Ilhan, Harun; Todica, Andrei; Michl, Marlies; Nadjiri, Jonathan; Paprottka, Philipp M
Abstract:: Trans-arterial radioembolization (TARE) is increasingly evaluated for unresectable intrahepatic cholangiocarcinoma (ICC). Not all ICC patients benefit equally well from TARE. Therefore, we sought to evaluate variables predicting progression-free survival (PFS) and overall survival (OS). Patients with non-resectable ICC underwent TARE and were treated with 90Y resin microspheres. Baseline characteristics, biochemical/clinical toxicities, and response were examined for impact on PFS and OS. A total of 103 treatments were administered to 73 patients without major complications or toxicity. Mean OS was 18.9 months (95% confidence intervals (CI); 13.9-23.9 months). Mean and median PFS were 10.1 months (95% CI; 7.9-12.2) and 6.4 months (95% CI; 5.20-7.61), respectively. Median OS and PFS were significantly prolonged in patients with baseline cholinesterase (CHE) ≥ 4.62 kU/L (OS: 14.0 vs. 5.5 months; PFS: 6.9 vs. 3.2 months; p < 0.001). Patients with a tumor burden ≤ 25% had a significantly longer OS (15.2 vs. 6.6 months; p = 0.036). Median PFS was significantly longer for patients with multiple TARE cycles (24.4 vs. 5.8 months; p = 0.04). TARE is a considerable and safe option for unresectable ICC. CA-19-9, CHE, and tumor burden have predictive value for survival in patients treated with TARE. Multiple TARE treatments might further improve survival; this has to be confirmed by further studies.
Zeitschriftentitel:: Cancers (Basel)
Jahr:: 2021
Band / Volume:: 13
Heft / Issue:: 21
Volltext / DOI:: doi:10.3390/cancers13215399
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/34771563
TUM Einrichtung:: 595; Fachgebiet Neuroradiologie (Prof. Zimmer); Professur für Interventionelle Radiologie (Prof. Paprottka)
BibTeX